dc.contributor.author | Bayraktar , Y | |
dc.contributor.author | Uzunalimoğlu , B | |
dc.contributor.author | Arslan , S | |
dc.contributor.author | Koseoğlu , T | |
dc.contributor.author | Kayhan , B | |
dc.contributor.author | Telatar , H | |
dc.date.accessioned | 2019-12-10T11:12:05Z | |
dc.date.available | 2019-12-10T11:12:05Z | |
dc.date.issued | 1993 | |
dc.identifier.issn | 0017-5749 | |
dc.identifier.uri | https://doi.org/10.1136/gut.34.2_Suppl.S101 | |
dc.identifier.uri | http://hdl.handle.net/11655/15009 | |
dc.description.abstract | This paper presents the preliminary results of a study designed to evaluate the effects of alpha interferon in chronic hepatitis B. After six months' treatment with interferon alfa-2b (5 million units (MU), three times weekly) 15 of 25 (60%) patients achieved seroconversion of hepatitis B e antigen, 17 (68%) normalised alanine aminotransferase (ALT) activity, and 15 (60%) showed a decrease in the inflammatory reaction on liver histology. No seroconversions occurred in the control group (n=10), and none of the control patients achieved a normal ALT or showed a reduction in the inflammatory reaction. Adverse effects were experienced by most patients who received interferon but none warranted stopping the treatment. | |
dc.language.iso | en | |
dc.publisher | British Med Journal Publ Group | |
dc.relation.isversionof | 10.1136/gut.34.2_Suppl.S101 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Gastroenterology & Hepatology | |
dc.title | Effects Of Recombinant Alpha-Interferon On Chronic Active Hepatitis-B - Preliminary-Results | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/conferenceObject | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Gut | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 34 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | S101 | |
dc.identifier.endpage | S101 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |